NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University Hospital, Essen
Sun Yat-sen University
University of Cologne
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fujian Cancer Hospital
Case Comprehensive Cancer Center
Sun Yat-sen University
Fujian Cancer Hospital
Ludwig-Maximilians - University of Munich
National Cancer Institute, Naples
Hospital Israelita Albert Einstein
Changhai Hospital
Catharina Ziekenhuis Eindhoven
Shandong Cancer Hospital and Institute
Fudan University
Nanfang Hospital, Southern Medical University
Eastern Cooperative Oncology Group
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Fujian Cancer Hospital
Salah Azaïz Cancer Institute
Cinnagen
National Cancer Institute, Naples
Zhujiang Hospital
Sixth Affiliated Hospital, Sun Yat-sen University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tanta University
Ludwig-Maximilians - University of Munich
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
University of Southern California
The First Affiliated Hospital with Nanjing Medical University
Shanghai Zhongshan Hospital
Sun Yat-sen University
Alliance for Clinical Trials in Oncology
Tarveda Therapeutics
First Affiliated Hospital of Wenzhou Medical University
Australasian Gastro-Intestinal Trials Group
CSPC Ouyi Pharmaceutical Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital
Khon Kaen University
West China Hospital
Shanghai Zhongshan Hospital
Centro Ricerche Cliniche di Verona
Sixth Affiliated Hospital, Sun Yat-sen University
Sun Yat-sen University
Grupo Espanol Multidisciplinario del Cancer Digestivo
Massachusetts General Hospital
China Medical University, China
China Medical University, China
China Medical University, China